|
Market Closed -
Nasdaq
00:00:00 15/08/2026 +04
|
After hours 01:03:01 | |||
| 76.83 USD | -0.04% |
|
76.86 | +0.03% |
Company Valuation: Forte Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,936 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 298.09% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,936 | 1,936 | 1,936 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 298.09% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -19.4x | -18.9x | -18.4x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 1.2x | -6.81x | -7.89x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -21.2x | -18x | -15.2x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -3.965 | -4.075 | -4.17 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -91.11 | -107.4 | -127.6 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -91.11 | -107.4 | -127.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 76.86 | 76.86 | 76.86 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 25,186 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -19.38x | - | - | - | 1.88B | |
| 21.38x | 7.5x | 15.3x | 1.35% | 71.56B | |
| 31.01x | 7.89x | 24.08x | 0.05% | 54.43B | |
| -79.85x | 14.92x | -76.15x | -.--% | 27.59B | |
| 30.34x | 5.94x | 15.73x | -.--% | 23.91B | |
| -14.5x | 5.07x | -6.61x | -.--% | 23.14B | |
| 25.57x | 4.84x | 16.25x | -.--% | 18.65B | |
| 58.2x | 20.62x | 42.08x | 0.07% | 18.64B | |
| -1217.84x | 38.05x | -15079.66x | -.--% | 16.01B | |
| 15.7x | 4.62x | 10.79x | -.--% | 12.54B | |
| Average | -114.94x | 12.16x | -1,670.91x | 0.16% | 26.83B | |
| Weighted average by Cap. | -60.99x | 10.43x | -899.29x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
